
    
      The phase II treatment schema for patients in 1st CR or ≥ 2nd CR will be the same for the
      vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/ m^2 and with
      no DLT assessment. Patients will be randomized to starting oral β-glucan in week 1 or in week
      6.
    
  